Hoskin D W, Stankova J, Anderson S K, Roder J C
Department of Microbiology, Dalhousie University, Halifax, Canada.
Cancer Immunol Immunother. 1989;29(3):226-30. doi: 10.1007/BF00200000.
Binding of CD3-specific antibodies to the TcR-CD3 complex results in T cell activation without the need for occupation of the T cell receptor (TcR) by its ligand. Murine T cells activated in this manner will kill a broad range of tumor targets but not normal lymphoblasts. We report here that non-specific cytolytic activity can be induced in vivo by a single i.p. injection of nonlytic 145-2C11 anti-CD3 monoclonal antibody. At least three populations of effector cells are activated in these mice. These are non-MHC (major histocompatibility complex) restricted cytotoxic T lymphocytes, activated natural killer cells, and lymphokine-activated killer cells. Anti-CD3 treatment is effective in significantly reducing the number of lung tumor nodules which form in mice inoculated with oncogenic ras-transfected syngeneic 10T1/2 fibroblasts. Anti-CD3-activated killer cells may, therefore, find a future role in cancer immunotherapy.
CD3特异性抗体与TcR-CD3复合物结合会导致T细胞活化，而无需其配体占据T细胞受体（TcR）。以这种方式活化的小鼠T细胞会杀死多种肿瘤靶标，但不会杀死正常淋巴细胞。我们在此报告，通过单次腹腔注射非溶细胞性145-2C11抗CD3单克隆抗体可在体内诱导非特异性细胞溶解活性。在这些小鼠中至少激活了三类效应细胞。它们是不受主要组织相容性复合体（MHC）限制的细胞毒性T淋巴细胞、活化的自然杀伤细胞和淋巴因子激活的杀伤细胞。抗CD3治疗可有效显著减少接种致癌性ras转染的同基因10T1/2成纤维细胞的小鼠中形成的肺肿瘤结节数量。因此，抗CD3激活的杀伤细胞可能在癌症免疫治疗中发挥未来作用。
